Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Isoray Featured On Discovery Channel

|Includes: IsoRay, Inc. (ISR)

For those of you who have been following Isoray, an important video was just aired on the Discovery Channel, featuring Isoray's lead product, cesium 131. Here is the link:

http://link.brightcove.com/services/player/bcpid1501665922001?bckey=AQ~~,AAAAAAABkyc~,PFOoGLfSWhaAwp3PhcPV3VgWFY-uqT1m&bctid=1642707491001

if you're not familiar with the benefits of cesium 131 for treating prostate cancer, read this article:

https://seekingalpha.com/article/308614-isoray-impressive-98-success-treating-prostate-cancer

What I like about the video, is that somehow the Discovery Channel "discovered" Isoray's product, and decided to do a story.

In my opinion, cesium 131 will eventually become the industry standard for treating prostate cancer, and Isoray will benefit tremendously. It just takes a while, and videos like this will help tremendously. If doctors are resistant to making the switch to cesium 131, patients will certainly begin to pressure them.

Also, today Isoray announced the company has earned the European CE Mark, allowing for immediate sales of the company's GliaSite products in 31 European countries. This will definitely have a positive affect on top line revenue. Once again, Isoray's CEO, Dwight Babcock continues to impress me with his execution.

For all you Virnetx investors who were able to buy Isoray shares at $.40 last month, congratulations.

Disclosure: I am long ISR.